{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Cellgram-ED",
            "NStudiesAvail": 430108,
            "NStudiesFound": 2,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 2,
            "FieldList": [
                  "DesignTimePerspective",
                  "DesignWhoMasked",
                  "DetailedDescription",
                  "DispFirstPostDate",
                  "DispFirstPostDateType",
                  "DispFirstSubmitDate",
                  "DispFirstSubmitQCDate",
                  "EligibilityCriteria",
                  "EnrollmentCount",
                  "EnrollmentType",
                  "EventGroupDeathsNumAffected",
                  "EventGroupDeathsNumAtRisk",
                  "EventGroupDescription",
                  "EventGroupId",
                  "EventGroupOtherNumAffected",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant"
                        ],
                        "DetailedDescription": [
                              "To evaluate the efficacy and efficacy for 12 months after a single dose of Cellgram-ED in patients with erectile dysfunction after radical prostatectomy."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nMen aged 19 to 80 years old at screening\nPatients who maintained normal foot function before prostatectomy and are interested in restoring sexual function after surgery\nPSA level <10 ng/mL before prostatectomy\nPathological Gleason sum \u2264 7(3+4 or 4+3) factor during prostatectomy\nLocal lesions that did not metastasize during prostatectomy (pT2, N0, M0 stage) factors\nPatients more than 1 year after prostatectomy and PSA \u2264 0.04 ng/mL when screened without additional treatment other than surgery\nWho cannot satisfy sexual activity(more than 4 times) with proper sexual stimulation in spite of taking maximum dose of oral PDE5I(phos-phodiesterasetype-5 inhibitors) within last 8weeks.\n\nTotal score of 10 or more and 17 or less in the EF (Erectile function) field* of the International Erectile Function Questionnaire\n\n* 1, 2, 3, 4, 5, 15 questions for EF erectile function in the international erectile function questionnaire\n\nPrevalence for erectile dysfunction at screening with more than 6 months\nWho are willing to engage in sexual activity more than 4 times a month and have a constant partner for at least 3 months\nWho do not have difficulty reading and understanding the contents of the questionnaire and who fill out a complete questionnaire\nA person who voluntarily agrees to participate in this clinical trial and has signed the consent form by the subject and the subject partner\n\nExclusion Criteria:\n\nSevere cardiovascular disease (angina pectoris, myocardial infarction, unstable arrhythmia, heart failure, etc.) at the screening visit\nWho cannot collect bone marrow due to bone marrow disease, etc.\nThose with the following medical history/companion diseases A. Gentamicin hypersensitivity reaction B. Solid cancer or malignant blood disease within 5 years prior to screening C. Clinically significant cognitive impairment, dementia or psychiatric disorder D. Alcohol or substance abuse E. Priapism F. Severe respiratory diseases (COPD, asthma, pneumonia, pulmonary embolism, pneumothorax, etc.) G. Stroke H. Systemic autoimmune disease\nThose with the following test results at the screening visit A. Liver disease or abnormal liver function (AST or ALT \u2265 3 times the normal upper limit of the organ) B. Severe renal impairment (serum creatinine\u2265 2 mg/dL) C. Positive factors for pathogenic microbial tests (Hbs Ag, HCV Ab, HIV Ab, Syphilis) D. Uncontrolled high blood pressure (systolic blood pressure >170 mmHg or diastolic blood pressure >100 mmHg) or hypotension (systolic blood pressure <90 mmHg, diastolic blood pressure <50 mmHg) E. Who are outside the normal range of tumor marker tests (PSA, CEA, AFP) F. Hemorrhagic tendency (PT and aPTT> ULN x 1.5) G. Untreated hypogonadism or serum testosterone hormone less than 200 ng/dL\nThose who possess the following therapeutic powers at screening A. Who are being treated for severe systemic or local infection B. Long-term use of anticoagulant (warfarin) (administered for more than 3 months as anticoagulant therapy) C. Vacuum compressor or intracavernous injection therapy within 7 days before screening (prostaglandin E1, papaverine, phentolamine, etc.) D. Immunosuppressants, alpha blockers or male hormones (androgens, anti-androgens) within 28 days prior to screening\nPenile anatomical malformations (ex: Peyronie's disease) or penile implants or penile vascular procedures\nWho are receiving drugs* that are expected to affect the results of this clinical trial when judged by the investigator\n\nIf the partner is a woman of childbearing potential, those who are not willing to use an appropriate contraceptive method** during the clinical trial period\n\n**Contraceptive administration and implantation or intrauterine device, infertility procedures (vapectomy, tubal ligation, etc.), blocking method (condom, contraceptive diaphragm, vaginal sponge or cervical cap)\n\nWho participated in other interventional clinical trials within 4 weeks prior to the screening visit and received clinical investigational drugs/investigational medical devices or received procedures\nWho have or will be administered other cell therapy products\nA person who is judged to be inappropriate to participate in this test when judged by the examiner\n\nRandom Inclusion Criteria:\n\nTotal score of 10 or more and 17 or less in the EF (Erectile function) field* of the International Erectile Function Questionnaire (IIEF)\n\n* 1, 2, 3, 4, 5, 15 questions for EF erectile function in the international erectile function questionnaire\n\nWho attempts sexual activity more than 4 times during the run-in period and has a failure rate (Sexual Encounter Profile) of 50% or more"
                        ],
                        "EnrollmentCount": [
                              "54"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04594850"
                        ]
                  },
                  {
                        "Rank": 2,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "Cellgram-ED is autologous bone marrow-derived mesenchymal stem cells ex vivo expanded for approximately 30 days. Ten patients (Diabetes -associated ED; 5 patients, Postprostatectomy; 5patients) will be injected Cellgram-ED directly into the intracavernous. Patient will be evaluated the safety and potential efficacy of MSC."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nPostprostatectomy Erectile Dysfunction\n\nA man aged 20 or older\nWho is willing to consent to participate in the study concerned with improving sexual activity after prostatectomy, the man has maintained normal sexual activity prior to prostatectomy\nPrior to prostatectomy PSA (prostate specific antigen) level<10 ng/mL\nAt the time of Prostatectomy, Pathological Gleason sum \u22647\nAt the time of Prostatectomy, Pathological stage \u2264 T2c\n2 years or more postprostatectomy patients with PSA level \u2264 0.04 ng/mL without additional therapy after prostatectomy\nWho cannot satisfy sexual activity(more than 4 times) with proper sexual stimulation in spite of taking maximum dose of oral PDE5I(phos-phodiesterasetype-5 inhibitors) within last 8weeks.\nIIEF, EF(erectile function) domain score is under 17\nHave a consistent partner who is willing to engage in sexual activity more than twice per month during the study.\n\nDiabetes-associated Erectile Dysfunction\n\nHbA1c is between 6.5% and 10% of man over 20 years of age with diabetes\nWho cannot satisfy sexual activity(more than 4 times) with proper sexual stimulation in spite of taking maximum dose of oral PDE5I within last 8weeks.\nIIEF, EF domain score is under 17\nWho is willing to consent to participate in the study concerned with improving sexual activity\nHave a consistent partner who is willing to engage in sexual activity more than twice per month during the study.\n\nExclusion Criteria:\n\nHistory of bone marrow disorders\nSerum AST/ALT > 3 X upper limit of normal or Creatinine > 1.5 X upper limit of normal\nHistory of hypersensitivity against a gentamycin\nSevere cardiovascular disease(angina, arrhythmia, cardiac failure, stroke), kidney failure, respiratory failure\nPositive for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and syphilis test\nPositive for PSA or CEA or AFP (Carcinoembryonic antigen), history of cancer in the last five years (except Prostatic cancer) Uncontrolled hypertension or hypotension (systolic blood pressure > 170 or < 90 mm Hg, diastolic pressure > 100 or < 50 mm Hg)\nHbA1c exhibit greater than 10%\nMen on anticoagulant treatment\nHave a severe infectious disease\nTestosterone level is less than 200ng/dl\nHave a penile implant or willing to it\nPatients with morphological changes of the penis\nPatient's partner is trying to conceive during the trial period\nUnwilling to participate in the study\nParticipating in other clinical trials in the past 30 days\nUnable to compliance with protocol\nInappropriate patients to participate in the study according to the investigator"
                        ],
                        "EnrollmentCount": [
                              "10"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT02344849"
                        ]
                  }
            ]
      }
}